EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Limited, each of which is a separate legal entity. Ernst & Young Limited is a Swiss company with registered seats in Switzerland providing services to clients in Switzerland.
Strong rebound in financing volume
In 2025, Swiss startups attracted more than CHF 3.3 billion in venture capital. This is an increase of over CHF 1 billion compared to 2024 and marks the second-highest annual total recorded in Switzerland since 2015, following the peak of nearly CHF 3.9 billion reached in 2022.
The number of financing rounds remained broadly stable at 515, up slightly from 513 in the previous year. Although this figure is still well below the 2022 record of 806 rounds, the stable deal count combined with rising volumes signals renewed investor confidence.
In 2025, the Swiss startup ecosystem recorded consistently high financing volumes above CHF 1.6 billion, effectively ending the downward trend observed since mid-2022.
A key driver behind the increase in total funding was the rise in large transactions. The number of mega deals (over CHF 100 million) increased from one in 2024 to five in 2025. Their total volume jumped from CHF 158 million to CHF 747 million, accounting for a substantial share of the overall growth.
Health remains the dominant sector
As in previous years, the health sector secured the largest share of venture capital in Switzerland. In 2025, health-related startups raised approximately CHF 1.5 billion, representing 44% of total investment volume.
In terms of deal activity, the health sector led with 147 financing rounds, followed by software & analytics with 135 rounds. Together, these two sectors accounted for 55% of all financing rounds in 2025.
A look at the largest individual transactions confirms the sector’s dominance: six of the ten biggest deals involved health companies. Moreover, the top four places in the ranking are occupied entirely by health startups: Sanoptis (CHF 235 million), Windward Bio (CHF 173 million), Distalmotion (CHF 120 million) and GlycoEra (CHF 112 million).